TBPHHIGH SIGNALRISK10-K

TBPH's lead drug candidate ampreloxetine failed its Phase 3 clinical trial, prompting management to wind down the program and accelerate a strategic review that includes a potential sale of the company.

The failure of the CYPRESS study represents a major setback for TBPH's pipeline and future growth prospects, as ampreloxetine was positioned as a potential first-in-class therapy. The Board's Strategic Review Committee is now acting "with urgency" to evaluate value-maximizing alternatives including a company sale, suggesting management believes independent operations may no longer be optimal.

Comparing 2026-03-23 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

The financial results reflect a challenging operational period with revenue declining substantially while operating losses improved meaningfully but remained negative. The company's balance sheet strengthened considerably with stockholders' equity growing 69% and total assets expanding 37%, though this occurred alongside a near-complete cessation of share buyback activity. The reduced accounts receivable and interest expense suggest lower business activity levels, consistent with the pipeline setback.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-99.8%
$197.1M$445K

Buyback activity reduced 99.8% — capital being redeployed elsewhere or cash conservation underway.

Operating Income
P&L
+92.3%
-$46.9M-$3.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Accounts Receivable
Balance Sheet
-72.5%
$2.3M$620K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
+69%
$175.5M$296.7M

Equity base grew 69% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
-68.4%
$48.6M$15.4M

Revenue declined 68.4% — significant demand weakness or market share loss warrants investigation.

Interest Expense
P&L
-63.1%
$6.4M$2.4M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Assets
Balance Sheet
+37.1%
$354.2M$485.6M

Asset base grew 37.1% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
+19.4%
$32.1M$38.3M

Current liabilities rose 19.4% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-23
PRIOR — 2025-03-07
ADDED
On February 28, 2026, there were 51,492,924 of the registrant s ordinary shares outstanding.
Recent Significant Developments Ampreloxetine Phase 3 Clinical Study Top-line Results On March 3, 2026, we announced that our ampreloxetine Phase 3 clinical study (CYPRESS) in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment composite score.
As a result of this outcome, we have decided to wind down the ampreloxetine program.
Strategic Review Committee In connection with the CYPRESS study results, the Strategic Review Committee of our Board of Directors (the "Committee") is accelerating its ongoing review of alternatives to maximize value for shareholders.
Since its formation in 2024, the Committee has been working on an ongoing basis with Lazard, its independent financial advisor, to evaluate opportunities available to the Company, including under multiple potential outcomes for the CYPRESS study.
+7 more — sign up free →
REMOVED
On February 21, 2025, there were 49,470,647 of the registrant s ordinary shares outstanding.
Ampreloxetine, our late-stage investigational once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension ( nOH ) in patients with Multiple System Atrophy ( MSA ), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients.
Recent Significant Developments YUPELRI Net Sales Growth In 2024, YUPELRI experienced net sales growth and reached launch-to-date highs in annual net sales and brand profitability.
Through the combined commercialization efforts with our partner Viatris Inc.
( Viatris ), total YUPELRI net sales increased by 8% to $238.6 million in 2024 compared to 2023.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →